Aclaris Therapeutics has dosed the first subject in the Phase IIa clinical trial of ATI-2138 to treat moderate to severe ...

The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can significantly improve symptoms.

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

Don’t let eczema control your child's life! Discover expert tips on managing atopic dermatitis for a happier, itch-free ...

Eczema is a chronic skin condition that shares similarities with autoimmune skin conditions, but it’s not an autoimmune ...

Introduction: Eczema, also known as atopic dermatitis, is a common skin condition characterized by dry, itchy skin. While ...

The US food and Drug Administration has approved lebrikizumab for treatment of atopic dermatitis in adults and children ages ...

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...

Ninety percent of people with moderate-to-severe symptoms of atopic dermatitis (atopic eczema) can effectively control their ...

Almirall has rolled out a new campaign for World Atopic Eczema Day, kicking off its “The T | Almirall has rolled out a new ...

The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...